SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Centessa Pharmaceuticals plc (CNTA) has a negative trailing P/E of -27.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 104.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.68%, forward earnings yield 0.96%. PEG 0.17 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (35/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -27.2); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -3.68%).
- Forward P/E 104.2 — analysts expect a return to profitability with estimated EPS of $0.38 for FY2029.
- PEG Ratio 0.17 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -3.68% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.96% as earnings recover.
- Analyst consensus target $38.60 (-2.5% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 33/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CNTA
Valuation Multiples
P/E (TTM)-27.2
Forward P/E104.2
PEG Ratio0.17
Forward PEG0.17
P/B Ratio10.19
P/S Ratio393.61
EV/EBITDA-28.2
Per Share Data
EPS (TTM)$-1.46
Forward EPS (Est.)$0.38
Book Value / Share$3.88
Revenue / Share$0.11
FCF / Share$-1.43
Yields & Fair Value
Earnings Yield-3.68%
Forward Earnings Yield0.96%
Dividend Yield0.00%
Analyst Target$38.60 (-2.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-438.3 |
0.00 |
0.00 |
0.00 |
- |
| 2020 |
-144.6 |
-2.55 |
497.70 |
0.00 |
- |
| 2021 |
-2.7 |
0.00 |
2.06 |
0.00 |
- |
| 2022 |
-1.3 |
0.03 |
0.86 |
0.00 |
- |
| 2023 |
-5.1 |
0.16 |
3.24 |
111.71 |
- |
| 2024 |
-8.1 |
-0.26 |
4.78 |
0.00 |
- |
| 2025 |
-17.2 |
0.59 |
6.44 |
226.28 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.07 |
$0.00 |
$-5.28M |
- |
| 2020 |
$-0.08 |
$0.00 |
$-10.66M |
- |
| 2021 |
$-4.24 |
$0.00 |
$-10.66M |
- |
| 2022 |
$-2.31 |
$0.00 |
$-216.21M |
- |
| 2023 |
$-1.57 |
$6.85M |
$-151.09M |
-2204.7% |
| 2024 |
$-2.06 |
$0.00 |
$-235.76M |
- |
| 2025 |
$-1.46 |
$15M |
$-197.53M |
-1316.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.65 |
$-1.81 – $-1.60 |
$3.09M |
$3.09M – $3.09M |
9 |
| 2027 |
$-1.76 |
$-2.01 – $-1.64 |
$33.33M |
$33.33M – $33.33M |
8 |
| 2028 |
$-1.50 |
$-4.01 – $1.40 |
$149.86M |
$147.42M – $152.3M |
11 |
| 2029 |
$-0.15 |
$-0.15 – $-0.15 |
$384.62M |
$384.62M – $384.62M |
4 |
| 2030 |
$2.70 |
$2.70 – $2.70 |
$956.13M |
$956.13M – $956.13M |
4 |
